Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012:5:23-35.
doi: 10.2147/IDR.S17432. Epub 2012 Jan 19.

Ceftaroline in complicated skin and skin-structure infections

Paul O Hernandez  1 , Sergio Lema, Stephen K Tyring, Natalia Mendoza
Affiliations

Ceftaroline in complicated skin and skin-structure infections

Paul O Hernandez et al. Infect Drug Resist. 2012.

Abstract

Ceftaroline is an advanced-generation cephalosporin antibiotic recently approved by the US Food and Drug Administration for the treatment of complicated skin and skin-structure infections (cSSSIs). This intravenous broad-spectrum antibiotic exerts potent bactericidal activity by inhibiting bacterial cell wall synthesis. A high affinity for the penicillin-binding protein 2a (PBP2a) of methicillin-resistant Staphylococcus aureus (MRSA) makes the drug especially beneficial to patients with MRSA cSSSIs. Ceftaroline has proved in multiple well-conducted clinical trials to have an excellent safety and efficacy profile. In adjusted doses it is also recommended for patients with renal or hepatic impairment. Furthermore, the clinical effectiveness and high cure rate demonstrated by ceftaroline in cSSSIs, including those caused by MRSA and other multidrug-resistant strains, warrants its consideration as a first-line treatment option for cSSSIs. This article reviews ceftaroline and its pharmacology, efficacy, and safety data to further elucidate its role in the treatment of cSSSIs.

Keywords: MRSA; Teflaro®; cSSSIs; ceftaroline; cephalosporin; complicated skin and skin-structure infections.

PubMed Disclaimer

References

    1. Maryland: Guidance for industry: Uncomplicated and complicated skin and skin structure infections: developing antimicrobial drugs for treatment. FDA.gov [homepage on the Internet] [Accessed September 26, 2011]. [cited Jul 1998]. Available from: http://www.fda.gov/ohrms/dockets/ac/03/briefing/3997B1_02_GFI-Diabetic%2....
    1. Maryland: Guidance for industry: Acute bacterial skin and skin structure infections: developing drugs for treatment. FDA.gov [homepage on the Internet] [Accessed September 26, 2011]. [cited Aug 2010]. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformati....
    1. Nathwani D. New antibiotics for the management of complicated skin and soft tissue infections: are they any better? Int J Antimicrob Agents. 2009;34(Suppl 1):S24–S29. - PubMed
    1. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillinresistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis. 2011;52(3):285–292. - PubMed
    1. DiNubile MJ, Lipsky BA. Complicated infections of skin and skin structures: when the infection is more than skin deep. J Antimicrob Chemother. 2004;53(Suppl 2):ii37–ii50. - PubMed